Used in the treatment of hereditary angioedema (HAE), this antibody targets and inhibits Factor XIIa, a key protein in the contact activation system. By blocking Factor XIIa, it prevents the excessive production of bradykinin, the mediator responsible for the swelling, pain, and inflammation seen during HAE attacks. It is administered subcutaneously and is designed for long-term prophylaxis to reduce the frequency of attacks. Its high specificity for Factor XII minimizes interference with other coagulation pathways, preserving normal hemostasis and reducing bleeding risk. This makes it a targeted, safe option for chronic management of HAE in adults and adolescents.